176 related articles for article (PubMed ID: 9399017)
1. Clinical applications of zolmitriptan (Zomig, 311C90).
Lipton RB; Stewart WF
Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
[TBL] [Abstract][Full Text] [Related]
2. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
3. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Rolan P
Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
[TBL] [Abstract][Full Text] [Related]
5. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Schoenen J; Sawyer J
Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
[TBL] [Abstract][Full Text] [Related]
6. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
Ferrari MD
Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
[TBL] [Abstract][Full Text] [Related]
7. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
Zagami AS
Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
9. A long-term study to maximise migraine relief with zolmitriptan.
Tepper SJ; Donnan GA; Dowson AJ; Bomhof MA; Elkind A; Meloche J; Fletcher PE; Millson DS
Curr Med Res Opin; 1999; 15(4):254-71. PubMed ID: 10640258
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
Solomon GD; Cady RK; Klapper JA; Earl NL; Saper JR; Ramadan NM
Neurology; 1997 Nov; 49(5):1219-25. PubMed ID: 9371897
[TBL] [Abstract][Full Text] [Related]
11. Zolmitriptan.
Can Fam Physician; 1999 Jun; 45():1491-4, 1497-501. PubMed ID: 10386213
[TBL] [Abstract][Full Text] [Related]
12. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
13. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD
Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525
[TBL] [Abstract][Full Text] [Related]
14. Zolmitriptan. Introduction.
Mathew N
Cephalalgia; 1997 Oct; 17 Suppl 18():1-3. PubMed ID: 9399011
[No Abstract] [Full Text] [Related]
15. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
Mauskop A; Farkkila M; Hering-Hanit R; Rapoport A; Warner J
Curr Med Res Opin; 1999; 15(4):282-9. PubMed ID: 10640260
[TBL] [Abstract][Full Text] [Related]
16. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
Edmeads JG; Millson DS
Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
Geraud GE
Eur Neurol; 1996; 36 Suppl 2():24-7. PubMed ID: 8791029
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness of 311C90 in the acute treatment of migraine.
Ferrari MD
Eur Neurol; 1996; 36 Suppl 2():4-7. PubMed ID: 8791025
[TBL] [Abstract][Full Text] [Related]
19. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan.
Limmroth V; Kazarawa Z; Fritsche G; Diener HC
Lancet; 1999 Jan; 353(9150):378. PubMed ID: 9950449
[No Abstract] [Full Text] [Related]
20. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
